What type of drug is Copiktra?
Copiktra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells (cancerous white blood cells).
Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, when they did not work or are no longer working.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are both cancers that affect lymphocytes, a type of white blood cell that plays an important role in the immune system.
CLL and SLL are essentially the same disease, with the only difference being the location where the cancer primarily occurs.
- CLL - most of the cancer cells are located in the bloodstream and the bone marrow (although lymph nodes and spleen are often involved)
- SLL - most of the cancer cells are located in the lymph nodes.
Copiktra also initially received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The approval for FL was based on overall response rate, with continued approval contingent upon verification of clinical benefit in confirmatory trials.
Secura Bio, Inc. announced the voluntarily withdrawal of follicular lymphoma indication for Copiktra in December 2021.
Read next
How will I feel after a Rituxan infusion?
After a Rituxan (rituximab) infusion you may experience certain side effects or adverse reactions that make you feel unwell. Common side effects include nausea, infusion-related reactions, and feeling tired. Continue reading
How long does it take for Rituxan to work?
Patients treated with Rituxan may notice an early response within 7-8 weeks of treatment. Most rheumatoid arthritis patients will notice some improvement in their symptoms, such as improvement in their levels of pain and inflammation, within 16 weeks of starting treatment with Rituxan. Continue reading
How does the drug Rituxan work?
Rituxan (rituximab) is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells, a type of white blood cell involved in immune responses. By binding to CD20, Rituxan helps eliminate these cells.
Continue readingSee also:
Related medical questions
- What is the difference between Truxima and Rituxan?
- Is Venclexta (venetoclax) chemotherapy?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- How do you prepare for a Rituxan infusion?
- How effective is Venclexta?
- Does Truxima make you gain weight?
- What causes infusion reactions to rituximab?
- How long do you take Venclexta for?
- What are the names of the BTK inhibitors?
- Does ibrutinib cause hair loss?
- Is Truxima a chemotherapy drug?
- How is Bendeka different to Treanda?
- How is Arzerra administered and how long to work?
- What is Arzerra used for and how does it work?
- Is Zydelig a chemotherapy drug?
- What is the difference between Rituxan and Rituxan Hycela?
- What is Zydelig used for and how does it work?
- Who makes Leukeran, and where is it made?
- What is the success rate of Breyanzi?
- How is Rituxan Hycela administered?
- How does Venclexta work?
- How long does it take for Jaypirca to work?
- How to apply for and use the Imbruvica copay card?
- What is CAR T-cell therapy and how does it work?
- What is the cost of Kymriah?
- What is the cost of Yescarta?
- What's the difference between Kymriah and Yescarta?
- How does Monjuvi work?
- How is Monjuvi given / administered?
- What is the success rate of Epkinly?
Drug information
Related support groups
- Duvelisib (1 questions, 3 members)
- Copiktra (1 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (27 questions, 57 members)
- Follicular Lymphoma (21 questions, 15 members)